We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Root Identified For Early-Onset Prostate Cancer

By LabMedica International staff writers
Posted on 28 Feb 2013
Early-onset prostate cancer (EOPC) requires early diagnosis and definitive treatment due to the long life expectancy of younger patients and their higher risk of dying from the disease.

Deep sequencing-based genomics analysis has been used to compare the genomic alteration landscapes of EOPC patients with those with the classical elderly-onset prostate cancer. More...


Scientists at the European Molecular Biology Laboratory (EMBL; Heidelberg, Germany) sequenced the entire genetic code of cells in 11 tumors from EOPC patients, comparing it with the code in tumors from seven patients with elderly-onset prostate cancer. They used these genomics data, together with a large-scale tissue microarray (TMA)-based validation platform, to pinpoint molecular features linked with early disease occurrence.

The investigators found that the receptor that binds testosterone, called the androgen receptor, is very active in tumors from young patients, causing a number of genes to rearrange and become cancer promoting. The genomes of elderly prostate cancer patients primarily showed abnormalities that were not caused by the androgen receptor's activity. Data from more than 10,000 additional patients showed that androgen receptor activity and corresponding gene rearrangements were indeed higher in younger patients.

Jan Korbel, PhD, the cosenior author of the study, said, "It's been unclear whether prostate cancer in the young is explainable by a different mechanism than prostate cancer in the elderly. Our study implicates a different cause of disease in young patients. Interestingly, young men have generally higher testosterone levels than elderly men, which raises the question of whether high physiological levels of testosterone in young men may be linked with early-onset prostate cancer, a question that we are keen to address in the future." The authors concluded that their findings demonstrate striking age-dependent differences in the mechanistic landscapes of structural genomic alterations in a common cancer. The study was published on February 11, 2013, in the journal Cancer Cell.

Related Links:

European Molecular Biology Laboratory




New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.